Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms [21] [20] GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations [18] [19] Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication [23] [24] Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations

Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: a systematic review and meta-analysis
The prevalence of sarcopenic obesity dropped from 49% at baseline to 33% [51]
This allowed for a comprehensive understanding of both immediate antimicrobial effects and the persistence of PTLs activity over time
Kim EJ, Lim SY, Lee HJ, Lee JY, Choi S, Kim SY, Kim JM, Shin IS, Yoon JS, Yang SJ, Kim SW